A covering letter must accompany all submissions to European Neuropsychopharmacology whereby it is understood to imply that the
data contained therein has not previously been published (except in abstract form) nor is being considered for publication elsewhere,
and that they have been tacitly or explicitly approved by the responsible authorities in the laboratory where the work was carried out.
Manuscripts submitted under multiple authorship are reviewed under the assumption that all listed authors concur with the submission
and have approved the final manuscript. If accepted, the paper shall not be published either whole or in part elsewhere in the same or
any other language without the consent of the Publisher.
Submission of Manuscripts European Neuropsychopharmacology
now proceeds totally online via an electronic submission system. By accessing the online submission system through the Author Gateway,
http://authors.elsevier.com/journal/euroneuro you will be guided stepwise through the creation and uploading of the various
files. When submitting a manuscript online, authors need to provide an electronic version of their manuscript and any accompanying figures
and tables.
Once the uploading is done, the system automatically generates an electronic (PDF) proof, which is then used for reviewing.
All correspondence, including the Editor's decision and request for revisions, will be processed through the system and will reach the
corresponding author by e-mail.
Once a manuscript has successfully been submitted via the online submission system authors may track
the status of their manuscript using the online submission system (details will be provided by e-mail). If your manuscript is accepted
by the journal, subsequent tracking facilities are available on Elsevier's Author Gateway, using the unique reference number provided
by Elsevier and corresponding author name (details will be provided by e-mail).
Authors may send queries concerning the submission
process or journal procedures to the appropriate Editorial Office:
For enquiries related to non-clinical manuscripts and related
editorial correspondence: ENP Secretariat, PO Box 85410, 3508 AK Utrecht, The Netherlands, e-mail: ENP@ecnp.nl
For
enquiries related to clinical manuscripts and related editorial correspondence: Professor Stuart A. Montgomery, European Neuropsychopharmacology,
PO Box 8751, London W13 8WH, UK, e-mail: ENP@samontgomery.co.uk
For further details on how to submit online, please
refer to the online EES Tutorial for authors or contact Elsevier's Author Support Team at authorsupport@elsevier.com.
Organisation of the manuscript
Only submissions in English will be considered. The title page should include: the title,
the name(s) and affiliation(s) of the author(s), and address for correspondence, and telephone/telefax numbers for editorial queries.
All articles should include an Abstract (a single paragraph of no more than 150 words), and 3-6 key words taken from Index Medicus
for abstracting and indexing purposes.
The text should be ordered under the following headings: 1. Introduction, 2. Experimental
procedures, 3. Results, 4. Discussion (may be combined with Results), Author Disclosures (see separete section on this), References.
Author Disclosure - NEW!!
Role of Funding Source. Authors are kindly requested to briefly describe the
role of the study sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement, authors should so
state.
eg, Funding for this study was provided by NIMH Grant XXXXXXX; the NIMH had no further role in study design; in the collection,
analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Following the Role of the Funding Source text, authors are required to declare their individual contribution to the manuscript
under a subheading Contributors.
eg, Author X designed the study and wrote the protocol. Author Y managed the literature
searches and analyses. Authors X and Z undertook the statistical analysis, and author W wrote the first draft of the manuscript. All
authors contributed to and have approved the final manuscript.
The third aspect of the Journal's new policy concerns the Conflict
of Interest. ALL authors are requested to disclose any actual or potential conflict of interest including any financial, personal
or other relationships with other people or organizations within three (3) years of beginning the work submitted that could inappropriately
influence, or be perceived to influence, their work.
Examples of potential conflicts of interest which should be disclosed include
employment, consultancies, stock ownership (except for personal investment purposes equal to the lesser of one percent (1%) or USD 5000),
honoraria, paid expert testimony, patent applications, registrations, and grants. If there are no conflicts of interest, authors should
state that there are none.
eg, Author Y owns shares in pharma company A. Author X and Z have consulted for pharma company B.
All other authors declare that they have no conflicts of interest.
Finally, before the references, the Journal will publish Acknowledgements, in a separate section, and not as a footnote on the title page.
eg, We thank Mr A, who kindly provided
the data necessary for our analysis, and Miss B, who assisted with the preparation and proof-reading of the manuscript.
NB.
During the online submission process the author will be prompted to upload these four mandatory author disclosures as separate items.
They will be automatically incorporated in the PDF builder of the online submission system. Please do not include in the main manuscripts.
Short Communications should not be more than 1500 words or equivalent space including figures and tables. They should
include an abstract of up to 75 words as well as key words and be concisely but adequately referenced.
Words to be printed in italics
are to be underlined.
Papers that do not conform to the general criteria for publication in European Neuropsychopharmacology
will be returned immediately to authors to avoid unnecessary delay in submission elsewhere.
The decision of the Editors is final;
the Editors cannot enter into correspondence about a paper that is considered unsuitable for publication.
Figures and Photographs
Figures and Photographs of good quality should be submitted online as a separate file. Please use a lettering that remains clearly readable
even after reduction to about 66%. For every figure or photograph, a legend should be provided. All authors wishing to use illustrations
already published must first obtain the permission of the author and publisher and/or copyright holders and give precise reference to
the original work. This permission must include the right to publish in electronic media.
Tables
Tables should be numbered
consecutively with Arabic numerals and must be cited in the text in sequence. Each table, with an appropriate brief legend, comprehensible
without reference to the text, should be typed on a separate page and uploaded online. Tables should be kept as simple as possible and
wherever possible a graphical representation used instead. Table titles should be complete but brief. Information other than that defining
the data should be presented as footnotes.
References (Harvard system)
Authors are responsible for the accuracy of the references. Only published articles and those
in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the
text. In the text a reference should be cited by author and date; where there are more than two authors, state first author's name followed
by et al. References should be listed alphabetically at the end of the paper and include, in the following order: all authors (surnames
followed by initials), year in parentheses, journal title (abbreviated according to the International List of Periodical Title Word Abbreviations),
volume number and inclusive page numbers. For books, the editors' names, book title, publisher and publisher's location should appear
before volume and page numbers. See the following examples of listing a journal article, monograph, and book chapter, respectively:
Examples:
Montgomery, S.A. and Green, M. (1988) Use of cholecystokinin in schizophrenia (Review). Psychol. Med. 18, 593-603.
Van Ree, J.M. and Matthysse, S. (1986) Psychiatric Disorders: Neurotransmitters and Neuropeptides. Elsevier, Amsterdam.
Herbert,
J. and McGregor, A. (1990) Neuroendocrine and behavioural effects of POMC peptides. In: Van Ree, J.M., Mulder, A.H., Wiegant, V.M. and
van Wimersma Greidanus, T.B. (Eds.), New Leads in Opioid Research. Excerpta Medica, Amsterdam, pp. 3-5.
Nomenclature Metric
units must be used throughout; laboratory units must be followed by SI (Systeme International) units. The generic name of the drug should
be used unless the specific trade name of the drug is directly relevant to the discussion. For receptor nomenclature, authors are referred
to the special supplement of Trends in Pharmacological Sciences devoted to this.
Ethics of experimentation Procedures involving experiments
on human subjects should be in accordance with the ethical standards of the Committee on Human Experimentation of the institution in
which the experiments were done or in accordance with the Helsinki Declaration of 1975. Procedures involving experimentation on animals
should be done in accordance with the guidelines of the institution in which the experiments were done.
Colour reproduction
European Neuropsychopharmacology is now also included in a new initiative from Elsevier: 'Colourful e-Products'. Through this initiative,
figures that appear in black & white in print can
appear in colour, online, in ScienceDirect at http://www.sciencedirect.com.
There is no extra charge for authors who participate.
For colour reproduction in print, you will receive information regarding
the costs from Elsevier after receipt of your accepted article. Please indicate your preference for colour in print or on the Web only.
Because of technical complications which can arise by converting colour figures to "grey scale" (for the printed version should you
not opt for colour in print) please submit in addition usable black and white versions of all the colour illustrations. For further
information on the preparation of electronic artwork, please see http://authors.elsevier.com/artwork/euroneuro.
Copyright Transfer
Upon acceptance of an article, you will be asked to transfer copyright (for more information on copyright
see http://authors.elsevier.com/journal/euroneuro. This transfer will ensure the widest possible dissemination of information.
If excerpts from other copyrighted works are included in the submission, the author(s) must obtain written permission from the copyright
owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier's Rights
Department, Philadelphia, PA, USA: phone (+1) 215 238 7869, fax (+1) 215 238 2239, e-mail healthpermissions@elsevier.com.
Requests for materials from other Elsevier publications may also be completed on-line via the Elsevier homepage http://www.elsevier.com/locate/permissions
Ethics of experimentation
Procedures involving experiments on human subjects should be in accordance with the ethical
standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accordance with the Helsinki
Declaration of 1975. Procedures involving experimentation on animals should be done in accordance with the guidelines of the institution
in which the experiments were done.
Proofs
One set of proofs will be supplied to the author to check for type-setting
accuracy: no changes to the manuscript will be allowed at this stage. Elsevier will do everything possible to correct your article and
publish it accurately and without delay. It is important, therefore, to ensure that all author corrections are marked clearly on your
proofs and returned to us in one communication. No additional corrections are possible following receipt by Elsevier of the first set
of marked up proofs. In the interests of publication time, authors should respond as quickly as possible, preferably by e-mail.
Reprints
25 free reprints are supplied per contribution; additional reprints may be ordered at the prices quoted on the order
form sent to the corresponding author.
